Cipla Q4 net profit slumps 55% YoY to Rs 555 crore, full-year PAT down 26%

Mumbai: Pharmaceutical major Cipla reported a 55% year-on-year decline in consolidated net profit to ₹555 crore for the quarter ended March; Total revenue from operations fell 3% to ₹6,541 crore. In FY26, revenue rose 2% year-on-year to ₹28,163 crore, while profit after tax fell 26% to ₹3,879 crore.

The board recommended a final dividend of ₹13 per share with a face value of ₹2 for the financial year ending March.

Also read: Shares of Cohance Lifesciences jump 20% on hiring of former Cipla CEO Umang Vohra
“We continue to make significant progress in the markets we focus on,” said Achin Gupta, MD and global CEO. “The core therapies in the branded prescription business delivered strong double-digit growth, the commercial generics business continued its strong growth momentum, and the core brands of the consumer healthcare business maintained leadership positions.”